Comparative analyses of plasma amyloid-β levels in heterogeneous and monomerized states by interdigitated microelectrode sensor system
暂无分享,去创建一个
Jee Hoon Roh | Dahye Jeong | Jae-Young Koh | Kyo Seon Hwang | Myung-Sic Chae | Yong Kyoung Yoo | Dongsung Park | Byung Hyun Byun | Jeong Hoon Lee | Y. Yoo | K. Hwang | J. Lee | J. Koh | Kyo-Chul Lee | J. Roh | Jinsik Kim | Myung-Sic Chae | Dahye Jeong | B. Byun | H. Kim | Sejin Lee | Youngsoo Kim | YoungSoo Kim | Hye Yun Kim | Sang Moo Lim | Sang-Moo Lim | Dongsung T. Park | Sejin Lee | Su Yeon Park | Kyo Chul Lee | Jeong Ho Ha | Jinny Claire Lee | Hye Jin Kim | Jinsik Kim | Seungyeop Baek | HoChung Jang | Kyeonghwan Kim | Won Woo Cho | Jae-Seung Kim | H. Kim | S. Baek | J. Lee | Hochung Jang | Kyeonghwan Kim | J. Ha | Jae-Seung Kim | Jeong-Hoon Lee | H. Kim | Jae-Seung Kim
[1] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[2] E. Oguni,et al. Amyloid β protein in plasma from patients with sporadic Alzheimer's disease , 1996, Journal of the Neurological Sciences.
[3] D. Na,et al. Normative data on the Korean version of the Boston Naming Test. , 1999, Journal of clinical and experimental neuropsychology.
[4] K. Blennow,et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.
[5] H. Wiśniewski,et al. Plasma amyloid β‐peptide 1–42 and incipient Alzheimer's disease , 1999 .
[6] P. Mehta,et al. Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease , 2001, Neuroscience Letters.
[7] K. Janda,et al. Biological tuning of synthetic tactics in solid-phase synthesis: application to A beta(1-42). , 2004, The Journal of organic chemistry.
[8] R. Deane,et al. RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Amyloid &bgr;-Peptide Clearance Through Transport Across the Blood–Brain Barrier , 2004, Stroke.
[9] K. Blennow,et al. The Effect of Simvastatin Treatment on the Amyloid Precursor Protein and Brain Cholesterol Metabolism in Patients with Alzheimer’s Disease , 2005, Dementia and Geriatric Cognitive Disorders.
[10] B. Reisberg,et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment , 2006, Neurobiology of Aging.
[11] W. M. van der Flier,et al. Longitudinal changes of CSF biomarkers in memory clinic patients , 2007, Neurology.
[12] Paul Maruff,et al. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .
[13] R. Tibshirani,et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.
[14] Simon A. Moss,et al. b -amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease , 2007 .
[15] Y. Matsuo,et al. Amyloid Oligomer Conformation in a Group of Natively Folded Proteins , 2008, PloS one.
[16] Jeffrey A. James,et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.
[17] T. Iwatsubo,et al. Aβ Immunotherapy: Intracerebral Sequestration of Aβ by an Anti-Aβ Monoclonal Antibody 266 with High Affinity to Soluble Aβ , 2009, The Journal of Neuroscience.
[18] G. Bitan,et al. Photo-induced cross-linking of unmodified proteins (PICUP) applied to amyloidogenic peptides. , 2009, Journal of visualized experiments : JoVE.
[19] K. Blennow,et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment , 2009, Neurobiology of Aging.
[20] J. Morris,et al. The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals , 2008, Cerebral cortex.
[21] Dong Jin Kim,et al. Regulation of in vitro Aβ1-40 aggregation mediated by small molecules. , 2010, Journal of Alzheimer's disease : JAD.
[22] David M. Rissin,et al. Single-Molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations , 2010, Nature Biotechnology.
[23] M. Vestling,et al. Amyloid-β Oligomer Specificity Mediated by the IgM Isotype – Implications for a Specific Protective Mechanism Exerted by Endogenous Auto-Antibodies , 2010, PloS one.
[24] Sang Won Seo,et al. Seoul Neuropsychological Screening Battery-Dementia Version (SNSB-D): A Useful Tool for Assessing and Monitoring Cognitive Impairments in Dementia Patients , 2010, Journal of Korean medical science.
[25] T. Tokuda,et al. High-molecular weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients , 2010, Alzheimer's & Dementia.
[26] T. Tokuda,et al. High-molecular weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients , 2010, Alzheimer's & Dementia.
[27] Sang Won Seo,et al. Volume reduction in subcortical regions according to severity of Alzheimer’s disease , 2011, Journal of Neurology.
[28] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.
[29] J. Kornak,et al. Amyloid Vs Fdg-pet in the Differential Diagnosis of Ad And , 2022 .
[30] R. Mayeux,et al. Meta-analysis of plasma amyloid-β levels in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.
[31] John Seibyl,et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.
[32] Tamara B Harris,et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. , 2011, JAMA.
[33] N. Schupf,et al. Nutrient intake and plasma β-amyloid , 2012, Neurology.
[34] J. H. Viles,et al. Human Serum Albumin Can Regulate Amyloid-β Peptide Fiber Growth in the Brain Interstitium , 2012, The Journal of Biological Chemistry.
[35] M. Verbeek,et al. Methods for analysis of amyloid-β aggregates. , 2012, Journal of Alzheimer's disease : JAD.
[36] Nick C Fox,et al. Brain imaging in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[37] C. Rowe,et al. Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing , 2013, Molecular Psychiatry.
[38] A. Jeromin,et al. CSF and Plasma Amyloid-β Temporal Profiles and Relationships with Neurological Status and Mortality after Severe Traumatic Brain Injury , 2014, Scientific Reports.
[39] M. Peng,et al. Plasma amyloid-β oligomers and soluble tumor necrosis factor receptors as potential biomarkers of AD. , 2014, Current Alzheimer research.
[40] Dong Jin Kim,et al. EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaques , 2015, Nature Communications.
[41] M. Sabbagh,et al. Age dependence of brain β-amyloid deposition in Down syndrome , 2015, Neurology.
[42] M. Sabbagh,et al. Age dependence of brain β-amyloid deposition in Down syndrome , 2015, Neurology.
[43] E. H. Jang,et al. White Matter Changes May Precede Gray Matter Loss in Elderly with Subjective Memory Impairment , 2016, Dementia and Geriatric Cognitive Disorders.
[44] E. H. Jang,et al. White Matter Changes May Precede Gray Matter Loss in Elderly with Subjective Memory Impairment. , 2016, Dementia and geriatric cognitive disorders.
[45] G. Taglialatela,et al. Non-Demented Individuals with Alzheimer's Disease Neuropathology: Resistance to Cognitive Decline May Reveal New Treatment Strategies. , 2016, Current pharmaceutical design.
[46] Jun-Young Lee,et al. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients , 2017, Medicine.
[47] Y. Yoo,et al. A highly sensitive plasma-based amyloid-β detection system through medium-changing and noise cancellation system for early diagnosis of the Alzheimer’s disease , 2017, Scientific Reports.